drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An autologous, genetically engineered T-cell therapy in which a patient’s T cells are modified to express chimeric antigen receptors targeting both BCMA (TNFRSF17) and GPRC5D. Engagement of these antigens triggers CD3ζ and costimulatory signaling, leading to T-cell activation, cytokine release, and perforin/granzyme-mediated lysis of multiple myeloma cells. Dual targeting is intended to reduce antigen escape in relapsed/refractory multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express chimeric antigen receptors targeting both BCMA (TNFRSF17) and GPRC5D. Binding to either antigen triggers CD3ζ and costimulatory signaling, leading to T‑cell activation, proliferation, cytokine release, and perforin/granzyme‑mediated lysis of multiple myeloma cells. Dual targeting is intended to reduce antigen escape in relapsed/refractory disease.
drug_name
BCMA/GPRC5D double CAR-T
nct_id_drug_ref
NCT06068400